- Home
- SNT vs ALVR Comparison
SNT vs ALVR Comparison
Compare SNT & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ALVR
- Stock Information
- Founded
- SNT 1965
- ALVR 2013
- Country
- SNT Canada
- ALVR United States
- Employees
- SNT N/A
- ALVR N/A
- Industry
- SNT Telecommunications Equipment
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNT Telecommunications
- ALVR Health Care
- Exchange
- SNT Nasdaq
- ALVR Nasdaq
- Market Cap
- SNT 64.6M
- ALVR 52.2M
- IPO Year
- SNT 1993
- ALVR 2020
- Fundamental
- Price
- SNT $3.36
- ALVR $9.28
- Analyst Decision
- SNT
- ALVR
- Analyst Count
- SNT 0
- ALVR 0
- Target Price
- SNT N/A
- ALVR N/A
- AVG Volume (30 Days)
- SNT 46.0K
- ALVR 29.1K
- Earning Date
- SNT 11-12-2024
- ALVR 03-14-2025
- Dividend Yield
- SNT N/A
- ALVR N/A
- EPS Growth
- SNT N/A
- ALVR N/A
- EPS
- SNT 0.06
- ALVR N/A
- Revenue
- SNT $34,455,000.00
- ALVR N/A
- Revenue This Year
- SNT N/A
- ALVR N/A
- Revenue Next Year
- SNT N/A
- ALVR N/A
- P/E Ratio
- SNT $57.79
- ALVR N/A
- Revenue Growth
- SNT 2.04
- ALVR N/A
- 52 Week Low
- SNT $1.08
- ALVR $7.96
- 52 Week High
- SNT $3.75
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- SNT 53.04
- ALVR 38.21
- Support Level
- SNT $3.06
- ALVR $7.96
- Resistance Level
- SNT $3.75
- ALVR $10.35
- Average True Range (ATR)
- SNT 0.22
- ALVR 1.15
- MACD
- SNT -0.06
- ALVR 0.01
- Stochastic Oscillator
- SNT 43.48
- ALVR 33.00
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.